Compare TAOP & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAOP | GTBP |
|---|---|---|
| Founded | 1993 | 1965 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 12.1M |
| IPO Year | 2012 | 2016 |
| Metric | TAOP | GTBP |
|---|---|---|
| Price | $1.30 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.0K | ★ 622.4K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.39 |
| 52 Week High | $8.78 | $3.73 |
| Indicator | TAOP | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 44.61 | 36.52 |
| Support Level | $1.23 | N/A |
| Resistance Level | $1.59 | $0.49 |
| Average True Range (ATR) | 0.22 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 17.35 | 3.37 |
Taoping Inc is a provider of cloud-app technologies for smart city IoT platforms, digital advertising delivery, and other internet-based information distribution systems in China. Its operating segment includes Cloud-based Technology (CBT), Blockchain Technology (BT), and Traditional Information Technology (TIT). It generates maximum revenue from the CBT segment. CBT segment includes cloud-based products and services offered to customers in the private sector including new media, healthcare, education, and residential community management.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.